BioNTech SE · NASDAQ:BNTX
BioNTech — 44th J.P. Morgan Healthcare Conference (January 2026)
36 slides from BioNTech's conference presentation, Jan 13, 2026
Slide 1: Translating Science into Survival
Translating Science into Survival Prof. Dr. Ugur Sahin, M.D., CEO & Co-founder, BioNTech 44th J.P. Morgan Healthcare Conference January 13, 2026
Slide 2: This Slide Presentation Includes Forward-Looking Statements
This Slide Presentation Includes Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: BioNTech’s expected revenues and net profit/
Slide 3: Continuing to Execute on BioNTech's Strategy
Continuing to Execute on BioNTech’s Strategy COVID-19 Vaccine Addressing Oncology Focused Infectious Global Impact Unmet Medical Need Disease Innovation 5 25 16 6 Billion vaccine Ongoing Clinical High unmet doses Phase 2 & programs3 need clinical distributed1 > Phase 3 trials2 programs4 In-House GMP
Slide 4: 2025 Achievements: Strong Performance and Pipeline Momentum
2025 Achievements: Strong Performance and Pipeline Momentum COVID-19 Market Advanced Key Executed Key Strengthened Leadership Oncology Programs Strategic Deals Financial Position Launched Over 25 phase 2 & 3 Strategic BMS Increased 2025 variant-adapted oncology trials ongoing2 partnership revenue gu
Slide 5: Robust Multi-Year Study Shows mRNA COVID-19 Vaccine Life-Saving Impact
Robust Multi-Year Study Shows mRNA COVID-19 Vaccine Life-Saving Impact1 5 billion doses shipped LP.8.1-adapted Maintained leadership to >180 countries vaccine launched with > 50% Real-world study of 27 million adults: in 69 markets market share3 and territories2 74% lower risk of death from severe C
Slide 6: Late-Stage Clinical Execution Momentum Towards Multiple Readouts
Late-Stage Clinical Execution Momentum Towards Multiple Readouts Number of ongoing Phase 2 and 3 oncology trials 4k Patients enrolled in ongoing Phase 2 & 25 3 oncology trials 1 12 15 Phase 2 & 3 10 readouts expected in 2026-2027 2023 2024 2025 Active portfolio management sets high bar for late-stag
Slide 7: Strong Financial Position Drives Sustainable Oncology Innovation
Strong Financial Position Drives Sustainable Oncology Innovation COVID-19 Vaccine Financial Cash Resource Revenue Strength Balance Allocation High-margin cash- Strengthened P&L €17.2 billion cash Active portfolio generative COVID-19 through profit- balance1 de-risks management vaccine business and c
Slide 8: Oncology Late-Stage Acceleration
Oncology 1 Late-Stage Acceleration Key late-stage data readouts expected for first wave of oncology assets Focus in 2026 2 Combination Therapy Momentum Novel-novel pumitamig1 combination data readouts expected 3 Modalities to Disease Areas Transition to a focused disease area specific approach 1. Pa
Slide 9: Building a Multi-Product Oncology Company by 2030
Building a Multi-Product Oncology Company by 2030 Tumor Type Incidence1 Assets Late-Stage / Pivotal Trials Pumitamig2 ROSETTA Lung-02 1L, 2L+ NSCLC 400k Lung Gotistobart3 PRESERVE-003 1L ES-SCLC 80k Pumitamig2 ROSETTA Lung-01 1L TNBC – all comers 25k Pumitamig2 Phase 3 in China Breast 1L TNBC – CPS
Slide 10: Strategic Oncology Multi-Modal Immunotherapy Approach
Strategic Oncology Multi-Modal Immunotherapy Approach • Focus on the critical IO pathways Immunomodulators • Targeting different complementary pathways in cancer immunity cycle may promote a durable anti-tumor effect • Precise and potent Synergy1 Synergy1 modalities for fast onset tumor reduction Sp
Slide 11: Immunomodulator, ADC, and mRNA Immunotherapy Key Assets
Immunomodulator, ADC, and mRNA Immunotherapy Key Assets Late-stage aPD-L1/ BNT314/ Pumitamig3 aEpCAM/a4-1BB program aVEGF GEN10597 Early-stage Immunomodulators Gotistobart5 aCTLA-4 BNT3213 aTIGIT/aPVRIG program BNT317 aPD-1/aCD39 BNT3215 aEGFR/acMET Synergy1 Synergy1 Trastuzumab Space aHER2 ADC pami
Slide 12: Unique Opportunity to Shape Next Wave of Solid Tumor Therapy
Unique Opportunity to Shape Next Wave of Solid Tumor Therapy Pumitamig1 Gotistobart2 BNT324/DB-13113 Bispecific antibody targeting TME-selective regulatory Novel pan-tumor ADC PD-L1 and VEGF-A with T cell-depleting antibody targeting B7H3 with next-gen IO backbone targeting CTLA-4 favorable safety p
Slide 13: Unique Opportunity to Shape Next Wave of Solid Tumor Therapy: Pumitamig
Unique Opportunity to Shape Next Wave of Solid Tumor Therapy Pumitamig1 Bispecific antibody targeting PD-L1 and VEGF-A with next-gen IO backbone potential Partnered with: 1. Bristol Myers Squibb; 2. OncoC4; 3. Duality Bio 13
Slide 14: Pumitamig: Differentiated Pan-Tumor PD-L1 x VEGF-A Bispecific Antibody
Pumitamig: Differentiated Pan-Tumor PD-L1 x VEGF-A Bispecific Antibody Differentiated MoA Anti-VEGF-A Enhanced dual blockade of PD-L1 and VEGF-A, mediated by a single bispecific molecule LALA silencing mutations Clinical evidence Anti-PD-L1 VHH Stable linkers PD-L1/VEGF-A Studied in 18 tumor types a
Slide 15: Pumitamig Showed Favorable Efficacy in Global Phase 2 Trials
Pumitamig Showed Favorable Efficacy in Global Phase 2 Trials 1L ES-SCLC (Global) 1L+ TNBC (Global) 20 60 Treatment Group tumor size baseline (%) Best percent change in PD Best Change from Baseline (%) 0 40 PD Cohort 1 – 15mg/kg: 1L Cohort 1 – 20mg/kg: 1L SD 20 SD Cohort 1 – 15mg/kg: 2L+ Cohort 1 – 2
Slide 16: Executing a Parallel Three-Wave Strategy to Build a Proprietary IO Franchise
Executing a Parallel Three-Wave Strategy to Build a Proprietary IO Franchise Establish Expand Elevate SCLC Registrational-Intent Combining with ADCs targeting: 1L Ph3 (Global) 1L Gastric Ph2/3 (Global) HER2 HER3 2L Ph3 (China) 1L CRC Ph2/3 (Global) TROP2 EGFR/HER3 1L/2L Ph2 (Global) 1L HNSCC Phase 2
Slide 17: Pumitamig Offers Potential to Replace and Expand Reach of First-Generation IO
Pumitamig Offers Potential to Replace and Expand Reach of First-Generation IO Replace Expand Anti-PD-(L)1 approved Anti-PD-(L)1 not approved CRC (MSI-H) Gastric HCC Breast (non TNBC) TNBC PD-L1 > 10% HNSCC/nasopharyngeal Endometrial 1.5M 2.0M TNBC PD-L1 < 10% RCC ~ Melanoma Prostate ~ new cancer cas
Slide 18: Unique Opportunity to Shape Next Wave of Solid Tumor Therapy: Gotistobart
Unique Opportunity to Shape Next Wave of Solid Tumor Therapy Gotistobart2 TME-selective regulatory T cell-depleting antibody targeting CTLA-4 Partnered with: 1. Bristol Myers Squibb; 2. OncoC4; 3. Duality Bio 18
Slide 19: Gotistobart is a Tumor-Selective Treg Depleter Targeting CTLA-4
Gotistobart is a Tumor-Selective Treg Depleter Targeting CTLA-4 Gotistobart1 Functional Characteristics Differentiated MoA pH-sensitive binding to CTLA-4 Selective killing of regulatory T cells (Tregs) in the tumor microenvironment Fc engineered, ADCC enhanced IgG1 antibody Clinical evidence Studied
Slide 20: Gotistobart Phase 2 Data Show Survival Benefit in CPI-Treated Squamous NSCLC
Gotistobart Phase 3 Data Show Survival Benefit in CPI-Treated Squamous NSCLC PRESERVE-003 trial stage 1 data: gotistobart1 reduces risk of death by 54% compared with docetaxel 100 Overall Survival Gotistobart Docetaxel 90 (n=45) (n=42) 80 Gotistobart OS Events, n (%) 17 (37.8) 28 (66.7) 63.1 (46.9–7
Slide 21: Squamous NSCLC Remains an Area of High Unmet Need
Squamous NSCLC Remains an Area of High Unmet Need ~55k Metastatic squamous NSCLC seen as #1 area of unmet need in NSCLC2 squamous NSCLC Limited treatment options for squamous NSCLC patients initiate 1L treatment patients without actionable genetic alterations (non-AGA population)1 In 2L, current che
Slide 22: Unique Opportunity to Shape Next Wave of Solid Tumor Therapy: BNT324/DB-1311
Unique Opportunity to Shape Next Wave of Solid Tumor Therapy BNT324/DB-13113 Novel pan-tumor ADC targeting B7H3 with favorable safety profile Partnered with: 1. Bristol Myers Squibb; 2. OncoC4; 3. Duality Bio 22
Slide 23: BNT324/DB-1311 B7H3-Targeted ADC with Pan-Tumor Potential
BNT324/DB-1311 B7H3-Targeted ADC with Pan-Tumor Potential B7H3 is overexpressed in multiple tumor types B7H3-targeting ADC with DAR=6 and novel topoisomerase inhibitor Clinical evidence 600+ patients treated with BNT324/DB-13111 across 10+ indications Antitumor activity in multiple tumor types2 Favo
Slide 24: BNT324/DB-1311 Shows a Favorable Safety Profile Across Tumors
BNT324/DB-1311 Shows a Favorable Safety Profile Across Tumors TRAEs in ≥10% of overall patients Treatment-related ILD/pneumonitis rate Nausea 48.7 1.7 Indication All tumor types Anemia 31.9 4.2 Dose (at Q3W) 6 mg/kg Neutrophil count ↓ 23.5 5.9 N 224 Fatigue 12.6 Median duration of treatment (months)
Slide 25: BNT324/DB-1311 mCRPC Data Demonstrates Strong Antitumor Activity
BNT324/DB-1311 mCRPC Data Demonstrates Strong Antitumor Activity Phase 1/2 data in heavily pretreated mCRPC patients 6 mg/kg Overall 6 mg/kg 40 (n=73) (n=38) 20 Response evaluable, n 52 24 ORR, (%) 42.3 41.7 0 Best change from baseline cORR, (%) 30.8 29.2 in sum of -20 target lesion diameter (%) DCR
Slide 26: Evolving mCRPC Landscape Offers Significant Opportunity For New Treatments
Evolving mCRPC Landscape Offers Significant Opportunity For New Treatments 80k mCRPC is a leading cause of cancer related mortality drug treated mCRPC Docetaxel becoming 1L therapy of choice patients in US by 2040 Many patients are ineligible for docetaxel or wish to delay or avoid chemo ~$22B Need
Slide 27: Differentiated Drug Class Combinations to Exploit Synergistic Mechanisms
Differentiated Drug Class Combinations to Exploit Synergistic Mechanisms Immunomodulators ADC + IO mRNA + IO Synergy1 Synergy1 Space for curative approaches Targeted mRNA cancer therapies immunotherapies Synergy1 mRNA + ADC 1. Synergistic potential. 27
Slide 28: Novel Combinations to Expand Pumitamig Opportunity Across Cancer Types
Novel Combinations to Expand Pumitamig Opportunity Across Cancer Types Additional Lung Breast GU Gastrointestinal Gynecologic Cancers Melanoma HER2- BC GC/GEJ EGFRm Cervical HNSCC NSCLC NSCLC PDAC TNBC SCLC AGA- HR+/ GBM RCC CRC HCC OC Chemotherapy / SoC Pumitamig1 + T-Pam2 BNT324/DB-13112 BNT325/DB
Slide 29: mRNA Immunotherapy Can Induce Broad T Cell Response
mRNA Immunotherapy Can Induce Broad T Cell Response and Potentially Provide Survival Benefit iNeST: individualized Neoantigen- FixVac: Fixed Antigen Vaccine Specific immunoTherapy BNT116: FixVac for lung cancer Broad neoantigen specific T cell response BNT1163 + Anti-PD-1 exhibits encouraging induce
Slide 30: BioNTech Key Tumor Focus Areas to Address Significant Unmet Medical Needs
BioNTech Key Tumor Focus Areas to Address Significant Unmet Medical Needs ADC Pumitamig1 IO mRNA Lung Breast Genitourinary Gastrointestinal Gynecologic Additional Tumors Leveraging novel combinations to elevate solid tumor treatment outcomes 1. Partnered with Bristol Myers Squibb 30
Slide 31: Broadening BioNTech's Coverage of Lung Cancer to Maximize Pipeline Potential
Broadening BioNTech’s Coverage of Lung Cancer to Maximize Pipeline Potential NSCLC incidence Neoadj / Resectable 1L metastatic 2L+ metastatic 2030 U.S., EU4, U.K.1 ~400k Pumitamig1 + chemo IIT5 Gotistobart2 Pumitamig1 + chemo PRESERVE-003 (sq) Pumitamig1 + FixVac ROSETTA LUNG-02 NSCLC LuCa-MERIT-1 F
Slide 32: Catalyst-Rich Year Ahead with Multiple Expected 2026 Milestones
Catalyst-Rich Year Ahead with Multiple Expected 2026 Milestones Program Trial Phase Indication Single arm Phase 2 2L+ HER2-expressing endometrial cancer Trastuzumab pamirtecan4 Phase 36 Chemo naïve HR+ HER2-low breast cancer Phase 36 2L+ sqNSCLC Gotistobart2 Late-Stage Trial Readouts7 Phase 2 2L+ mC
Slide 33: Building a Multi-Product Oncology Company by 2030
Building a Multi-Product Oncology Company by 2030 Targeting 17+ Late-stage / Pivotal Trial Readouts Through 2030+ Informing Multiple Launch Opportunities Tumor Type Incidence1 Assets Late-Stage / Pivotal Trials Expected Data Readouts2 2026 2027 2028 2029 2030+ Pumitamig3 ROSETTA Lung-02 1L NSCLC 400
Slide 34: Advanced Strategy, Matured Pipeline & De-risked Development
BioNTech Oncology Vision: Translating Science into Survival 2025 2026 – 2029 2030 Advanced Strategy, Drive Oncology Diversified Multi- Matured Pipeline & Execution at Product Company De-risked Development Scale & Speed Progressed key programs into Advance combination therapy Build a diversified, mul
Slide 35: Thank you
aaa thank you BIONT=Cr
Slide 36: Abbreviation Directory
Abbreviation Directory 4-1BB CD137 FixVac Fixed Antigen Vaccine (sq) NSCLC (sqamous) Non-small cell lung cancer nL nth line (m)FU (median) Follow-up time OC Ovarian cancer a Anti G7 Canada, France, Germany, Italy, Japan, Great Britain, USA (c)ORR (confirmed) Objective response rate ACC Adenoid cysti
BioNTech — 44th J.P. Morgan Healthcare Conference (January 2026) on 6ix